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ABSTRACT
Between February 1997 and December 2002, 3340 hospitalised patients yielded samples positive for
Proteus mirabilis, of whom 45 (1.3%) were colonised ⁄ infected by P. mirabilis producing extended-
spectrum b-lactamases (ESBLs). The gross incidence of patients colonised ⁄ infected by ESBL-producing
P. mirabilis was 1.61 ⁄ 105 days of hospitalisation, with 20% of isolates being collected from patients in
urology wards, most frequently (53.3%) from urine samples. Seventeen (37.7%) of the 43 isolates were
obtained from samples collected within 48 h of hospitalisation, indicating that they were community-
acquired. Isoelectric focusing assays and sequencing identiﬁed the TEM-24, TEM-92 and TEM-52 ESBLs.
Pulsed-ﬁeld gel electrophoresis revealed eight pulsotypes (I–VIII), with the two most common
pulsotypes, IV and VI, comprising ten (23.3%) and 12 (26.6%) isolates, respectively. These pulsotypes
were considered to represent epidemic strains and spread in various wards of the hospital.
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INTRODUCTION
Most infections caused by organisms producing
extended-spectrum b-lactamases (ESBLs) have
been described as nosocomial [1–4], although
such infections have also been described in non-
hospitalised patients [5–7]. Some data suggest
that infections caused by ESBL-producing
organisms might be an emerging problem in
outpatients in different countries [5–7]. Among
Enterobacteriaceae, Proteus mirabilis is the sec-
ond most common cause of urinary tract infec-
tions (UTIs), and is also an important cause of
nosocomial infections [8]. Wild-type strains of
P. mirabilis are usually susceptible to b-lactams.
However, a progressive increase in b-lactam
resistance, mediated by the production of
acquired b-lactamases, has occurred in this
species [9]. Plasmid-mediated ESBLs, including
TEM-type derivatives active against expanded-
spectrum cephalosporins, have also started
spreading in P. mirabilis [10]. In studies per-
formed in French hospitals, the proportion of
ESBL-producing isolates rose from 0.8% of
P. mirabilis isolates in 1991 [11] to 2.4% in
1996 [12], 3.7% and 6.9% in 1998 [13,14], and
14.2% in 2000 [8]. Within the genus, P. mirabilis
is by far the commonest species in which ESBLs
have been recognised, with occasional outbreaks
of infections caused by an epidemic resistant
strain and the spread of self-transferable plas-
mids from one organism to another [14]. The
present study used the technique of pulsed-ﬁeld
gel electrophoresis (PFGE) to assess the related-
ness of P. mirabilis isolates thought to be
responsible for outbreaks of nosocomial infec-
tions occurring in various wards in Amiens
University Hospital, France. Analysis of the
PFGE results was combined with data on
antimicrobial resistance patterns and b-lacta-
mase types.
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MATERIALS AND METHODS
Study population and bacteria
This was a retrospective 6-year study (February 1997 to
December 2002) of 122 978 patients admitted to Amiens
University Hospital, France. Bacteria isolated from these
patients were identiﬁed by the ID32 system (bioMe´rieux,
Marcy l’Etoile, France) and tested for ESBL production by
the double-disk synergy test (see below). Control strains
were Escherichia coli K12R111 producing TEM-1, P. mirabilis
CF529 producing TEM-92, and Enterobacter aerogenes produ-
cing TEM-24 and SHV-4. Plasmids pBR322 and pUC8 (TEM-
1-encoding plasmids of 4.362 kb and 2.678 kb, respectively),
EA 600 (a TEM-24-encoding plasmid of 85 kb) and CF529 (a
TEM-92-encoding plasmid of 50 kb) were used for compar-
isons.
Deﬁnitions
Catheter colonisation or infection was recorded when
P. mirabilis was cultured from an intravascular catheter
(‡ 103 CFU ⁄mL) according to the method of Brun-Buisson
[15] in the absence or presence, respectively, of clinical
symptoms. Symptomatic patients with positive urine cul-
tures (with fewer than three different pathogens isolated at
‡ 105 CFU ⁄mL, or ‡ 103 CFU ⁄mL associated with a leu-
kocyturia of > 104 ⁄mL) were considered to have UTI.
Asymptomatic patients with a permanent urinary catheter
and positive cultures (with fewer than three different
organisms isolated at ‡ 105 CFU ⁄mL, or without a bladder
catheter and two consecutive positive urine cultures of the
same microorganism at ‡ 105 CFU ⁄mL) were considered to
have asymptomatic bacteriuria [16]. When the interval from
admittance to isolation of the organism was £ 48 h, with no
previous hospitalisation, the infection was considered to be
community-acquired [17].
Antimicrobial susceptibility testing
Susceptibility to antimicrobial agents was tested by the disk
diffusion method on Mueller–Hinton agar (Bio-Rad, Ivry sur
Seine, France) according to the recommendations of the
Comite´ de l’Antibiogramme de la Socie´te´ Franc¸aise de
Microbiologie (CA-SFM) [18]. The antimicrobial agents used
in this study were ampicillin, ticarcillin, piperacillin, amoxy-
cillin–clavulanic acid, cephalothin, cefoxitin, latamoxef,
cefotaxime, ceftazidime, cefepime, cefpirome, imipenem,
aztreonam, gentamicin, tobramycin, netilmicin, amikacin,
isepamicin, trimethoprim–sulphamethoxazole, pipemidic acid
and oﬂoxacin. Bacteria were classiﬁed as susceptible, inter-
mediate or resistant as described by the CA-SFM [18]. MICs
of cefotaxime, ceftazidime, aztreonam, cefepime and cefpi-
rome were determined alone or in combination with a ﬁxed
concentration of clavulanate (2 mg ⁄L) by a serial two-fold
macrodilution procedure in Mueller–Hinton broth [19]. Dou-
ble-disk synergy tests were performed on Mueller–Hinton
agar as described previously [20], with a central amoxycillin–
clavulanic acid disk and disks of third-generation cephalo-
sporins (ceftazidime, cefepime and cefpirome) and a
monobactam (aztreonam) placed 30 mm (centre to centre)
from each other. The test was considered to be positive for
ESBL production when the bacterial growth had a ‘cham-
pagne cork’ appearance [20].
b-Lactamase assay
Isoelectric focusing of crude b-lactamase extracts was per-
formed with polyacrylamide gels containing ampholines of
pH 3.5–9.5 (ampholine PAG plate; Amersham Biosciences,
Little Chalfont, UK), using the procedure recommended by the
manufacturer, and an LKB 2117 Multiphor II apparatus
(Amersham Biosciences). The isoelectric points (pIs) of the
b-lactamases studied were determined by comparison with
reference enzymes (TEM-1, pI 5.4; TEM-92, pI 6; TEM-24, pI
6.5; and SHV-4, pI 7.8).
PFGE typing
Isolates were typed by determining PFGE SﬁI DNA macrore-
striction patterns with the Genepath Group 5 Reagent kit (Bio-
Rad) according to the manufacturer’s recommendations. PFGE
was performed with a contour-clamped homogeneous electric
ﬁeld system (CHEF-DR II, Bio-Rad) at 14C and 200 V for
19.7 h. Molecular Analyst software (Bio-Rad) was used to
analyse the DNA restriction patterns and determine their
similarity, based on calculation of the Dice similarity coefﬁ-
cient and use of the UPGMA algorithm (unweighted pair-
group method using arithmetic averages).
Agarose gel electrophoresis of plasmids and PCR
ampliﬁcations
Plasmid DNA was extracted with the RPM kit (QBiogene,
Calsbad, CA, USA), used according to the manufacturer’s
instructions. The crude extract was used directly for electro-
phoresis, which was performed in agarose 0.7% w ⁄v gels for
2 h at 100 V. Plasmid sizes were determined by comparison
with the plasmid size standards. PCR ampliﬁcations
and electrophoresis were performed as described previously
[21,22], but with primers TEM-A (5¢-ATGAGTATTCAA-
CATTTCCGTG) and TEM-B (5¢-TTACCAATGCTTAAT-
CAGTGAG). Initial denaturation was at 95C for 3 min,
followed by 30 cycles of 95C for 1 min, 55C for 1 min and
72C for 1 min, and a ﬁnal extension at 72C for 1 min.
DNA sequencing
The PCR-ampliﬁed blaTEM genes were puriﬁed using the QIA-
quick PCR puriﬁcation kit (QIAgen, Courtaboeuf, France)
according to the manufacturer’s recommendations, and were
then sequenced by PCR cycle sequencing with Dye Ex
chemistry (QIAgen), followed by automated analysis on an
ABI PRISM 310 Genetic analyser (Applied Biosystems, Foster
City, CA, USA).
RESULTS
Incidence of ESBL-producing P. mirabilis
infection
During the study period, 122 978 patients were
hospitalised, of whom 3340 (2.7%) yielded
samples positive for P. mirabilis. Of these, 45
(1.3%) patients were colonised ⁄ infected by
ESBL-producing isolates. These 45 patients were
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admitted to various wards of the hospital and
comprised 27 (60%) males and 18 (40%)
females, with a mean age of 63 years (range
23–94 years). The gross incidence of patients
infected by an ESBL-producing P. mirabilis
isolate was 1.61 ⁄ 100 000 days of hospitalisation.
The urinary tract was the most frequent site of
isolation (53.4%), followed by the bronchopul-
monary tract (17.7%) and miscellaneous sup-
puration sites (17.7%). Urological, miscellaneous
medical, surgical, long-stay and middle-stay
wards accounted for 62.2% of the cases of
colonisation ⁄ infection (Table 1). Patient records
revealed that P. mirabilis was associated with
other ESBL-producing microorganisms in 20%
(9 ⁄ 45) of infections: in UTIs, with E. coli (two
cases), Klebsiella pneumoniae (one case) and
Providencia stuartii plus E. coli (one case); in
bronchopulmonary tract infections, with
K. pneumoniae (one case) and Ent. aerogenes
(two cases); in femoral catheter infections, with
Ent. aerogenes (one case); and in suppuration,
with K. pneumoniae (one case). The following
risk factors were present in 24.2% (12 ⁄ 45) of
patients: indwelling urinary catheter (50%;
6 ⁄ 12); assisted ventilation (33.3%; 4 ⁄ 12); and
intravascular catheter (16.6%; 2 ⁄ 12). Seven
patients died in hospital (three patients hospi-
talised in the urology ward, one in the nephro-
logical intensive care unit (ICU), one in a
polyvalent ICU, one in the neurology ward
and one in the dermatology ward). Death was
not related directly to P. mirabilis infection, but
was probably caused by underlying diseases.
Table 1. Data for the ﬁrst ESBL-





(month ⁄ year) Specimen
Patient
gender Hospital ward
No. of days of hospitalisation
before isolatea
1 02 ⁄ 1997 Urine M Urology 9
2 03 ⁄ 1997 Urine M Maxillo-facial surgery 23
3 05 ⁄ 1997 Urine M Urology 1
4 07 ⁄ 1997 Suppuration M Neurosurgery 1
5 07 ⁄ 1997 Urine M Functional rehabilitation 72
6 10 ⁄ 1997 Jugular catheter M Long-stay ward 40
7 10 ⁄ 1997 Urine M Vascular surgery 25
8 12 ⁄ 1997 Suppuration M Long-stay ward 72
9 01 ⁄ 1998 Urine M Polyvalent ICU 93
10 06 ⁄ 1998 Urine F Middle-stay ward 25
11 08 ⁄ 1998 Suppuration M Dermatology 4
12 01 ⁄ 1999 Urine F Urology 1
13 02 ⁄ 1999 Bronchial ﬂuid F Neurology 13
14 04 ⁄ 1999 Bronchial ﬂuid F Respiratory medicine 1
15 04 ⁄ 1999 Urine M Functional rehabilitation 1
16 05 ⁄ 1999 Urine F Middle-stay ward 26
17 08 ⁄ 1999 Urine M Urology 12
18 10 ⁄ 1999 Urine M Plastic surgery 11
19 01 ⁄ 2000 Urine M Functional rehabilitation 1
20 03 ⁄ 2000 Suppuration M Urology 1
21 04 ⁄ 2000 Suppuration M Geriatrics 26
22 05 ⁄ 2000 Urine M Urology 1
23 07 ⁄ 2000 Urine F Dermatology 37
24 07 ⁄ 2000 Urine F Cardiology 4
25 08 ⁄ 2000 Urine F Geriatrics 10
26 09 ⁄ 2000 Bronchial ﬂuid M Polyvalent ICU 1
27 09 ⁄ 2000 Suppuration F Geriatrics 64
28 10 ⁄ 2000 Suppuration F Dermatology 1
29 12 ⁄ 2000 Femoral catheter F Nephrological ICU 315
30 01 ⁄ 2001 Urine F Neurosurgery 33
31 03 ⁄ 2001 Urine M Internal medicine 1
32 04 ⁄ 2001 Urine F Nephrological ICU 1
33 05 ⁄ 2001 Urine M Long-stay ward 34
34 05 ⁄ 2001 Urine M Urology 45
35 05 ⁄ 2001 Sputum F Geriatrics 2
36 06 ⁄ 2001 Bronchial ﬂuid M Respiratory ICU 1
37 02 ⁄ 2002 Urine M Urology 2
38 06 ⁄ 2002 Wound M Plastic surgery 18
39 07 ⁄ 2002 Blood M Urology 28
40 07 ⁄ 2002 Sputum F Geriatrics 2
41 07 ⁄ 2002 Renal abscess F Nephrology 4
42 10 ⁄ 2002 Sputum M Long-stay ward 1
43 10 ⁄ 2002 Bronchial ﬂuid M Respiratory medicine 1b
44 11 ⁄ 2002 Urine F Neurology 1b
45 12 ⁄ 2002 Suppuration F Dermatology 313
ICU, intensive care unit; M, male; F, female.
aThe median time to acquisition of ESBL in long-stay and rehabilitation wards was 32 days vs. 16.2 days in short-
stay wards.
bThese patients were hospitalised 2 months previously and the isolate was considered to be hospital-acquired.
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Seventeen (37.7%) ESBL-producing P. mirabilis
isolates were identiﬁed in samples collected with-
in 48 h of hospitalisation. These patients were
admitted from their respective homes, had not
been hospitalised during the previous 6 months
or transferred from another hospital, and were
considered to be community-acquired cases of
infection. Twenty-eight (62.3%) cases of P. mira-
bilis infection were identiﬁed ‡ 72 h after admis-
sion and were considered to be hospital-acquired.
Antimicrobial susceptibilities
The 45 P. mirabilis isolates gave a positive disk
potentiation when cefotaxime, ceftazidime, cefep-
ime, cefpirome and aztreonam disks were used
with amoxycillin–clavulanic acid. These isolates
showed decreased susceptibilities to amino-,
carboxy- and ureido-penicillins, most cephalospo-
rins (including cefotaxime, ceftazidime, cefepime,
cefpirome) and aztreonam, but remained suscept-
ible to cephamycins (cefoxitin, latamoxef) and
imipenem. b-Lactam MICs were increased for the
45 clinical isolates (Table 2) compared to the
reference strain E. coli ATCC 25922, which had
MICs £ 1 mg ⁄L. Variable susceptibility patterns
were observed for cefotaxime (MIC range
2–128 mg ⁄L), ceftazidime (4–64 mg ⁄L), cefepime
(2–64 mg ⁄L), cefpirome (2–32 mg ⁄L) and aztreo-
nam (2–32 mg ⁄L). For all isolates, the MICs of
cefotaxime, ceftazidime, cefepime, cefpirome and
aztreonam decreased to £ 0.25 mg ⁄L in the pres-
ence of clavulanic acid 2 mg ⁄L. MICs of cefoxitin,
latamoxef and imipenem for the same isolates
were 0.25–1, 0.06–0.25 and 0.25–0.5 mg ⁄L,
respectively. With regard to aminoglycosides,
62.2% of the 45 isolates were resistant to gentam-
icin, tobramycin and netilmicin, 20% were resist-
ant to tobramycin, netilmicin and amikacin, and
17.8% were resistant to gentamicin, tobramycin,
netilmicin and amikacin, suggesting the presence
of AAC(3), AAC(6¢), and AAC(3) + AAC(6¢),




Thepresence of ESBLswas suggestedby the results
of isoelectric focusing and synergy tests. All 45
isolates yielded amplicons in PCRs for blaTEM,
while none were positive in PCRs for blaSHV.
Sequencing of blaTEM genes was performed on
three isolates with b-lactamase pIs of 5.9, 6.0 and
6.5. Analysis of the deduced protein sequence,
compared to that of blaTEM-1, showed three amino-
acid substitutions for the pI 5.9 enzyme (Glu-
104 ﬁ Lys; Met-182 ﬁ Thr; Gly-238 ﬁ Ser)
and four amino-acid substitutions for the pI 6.0
enzyme (Gln-6 ﬁ Lys; Glu-104 ﬁ Lys;
Met-182 ﬁ Thr; Gly-238 ﬁ Ser). These protein
sequences are identical to those of TEM-52 and
TEM-92, respectively [21,23]. The enzyme of pI 6.5
had ﬁve substitutions reported previously [10]
(Gln-39 ﬁ Lys; Glu-104 ﬁ Lys; Arg-164 ﬁ
Ser; Ala-237 ﬁ Thr; Glu-240 ﬁ Lys), corres-
ponding to TEM-24. Overall, the results suggested
Table 2. Results of analytical isoelectric focusing and




characterisation MIC (mg ⁄L)
PFGE
patternspI Enzyme CTX CAZ FEP CPO ATM
1 6.5 TEM-24 2 4 2 2 2 VI
2 6.5 TEM-24 4 8 8 2 4 VI
3 6.5 TEM-24 8 16 32 2 16 VII
4 6.5 TEM-24 16 32 64 4 16 VII
5 6.5 TEM-24 32 64 8 2 8 I
6 6.5 TEM-24 16 64 8 8 8 VII
7 6.5 TEM-24 4 8 8 4 4 I
8 6.5 TEM-24 2 8 16 8 4 VI
9 6.5 TEM-24 8 64 16 16 2 VI
10 6.5 TEM-24 16 32 8 8 2 VI
16 6.5 TEM-24 2 4 2 16 2 I
20 6.5 TEM-24 2 4 2 2 4 III
24 6.5 TEM-24 8 16 4 8 4 II
25 6.5 TEM-24 4 16 2 8 8 II
26 6.5 TEM-24 4 8 2 4 8 II
28 6.5 TEM-24 4 32 2 4 16 VI
30 6.5 TEM-24 2 8 2 4 8 VI
32 6.5 TEM-24 8 64 4 8 16 VI
33 6.5 TEM-24 16 64 4 16 8 VI
34 6.5 TEM-24 8 32 4 16 16 V
38 6.5 TEM-24 4 16 4 16 8 IV
39 6.5 TEM-24 2 8 2 2 4 IV
40 6.5 TEM-24 2 4 2 2 2 IV
41 6.5 TEM-24 8 64 4 8 4 IV
45 6.5 TEM-24 8 16 2 4 2 IV
11 6.0 TEM-92 16 8 2 4 4 VII
12 6.0 + 5.9 TEM-92 + TEM-52 32 64 8 8 16 I
13 6.0 TEM-92 128 32 64 32 32 VI
14 6.0 TEM-92 64 16 32 32 32 I
15 6.0 TEM-92 64 4 32 16 16 I
17 6.0 TEM-92 32 8 16 16 8 III
18 6.0 TEM-92 32 8 8 8 4 V
19 6.0 TEM-92 128 16 64 4 2 I
29 6.0 TEM-92 128 32 64 2 8 VI
31 6.0 TEM-92 32 4 8 2 8 VI
35 6.0 TEM-92 32 4 8 16 8 IV
36 6.0 TEM-92 64 16 4 16 8 IV
37 6.0 TEM-92 32 4 4 2 2 IV
42 6.0 TEM-92 128 8 2 4 4 IV
43 6.0 TEM-92 16 4 2 2 2 IV
44 6.0 TEM-92 32 4 8 2 2 VIII
21 5.9 TEM-52 64 8 8 32 16 III
22 5.9 TEM-52 32 8 8 32 16 III
23 5.9 TEM-52 64 8 8 16 8 II
27 5.9 TEM-52 16 4 8 16 8 II
CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; CPO, cefpirome; ATM,
aztreonam; PFGE, pulsed-ﬁeld gel electrophoresis.
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that 24 (55.6%) isolates produced TEM-24, 15
(33.3%) produced TEM-92, four (8.8%) produced
TEM-52, and one (2.2%) (no. 12) produced both
TEM-92 and TEM-52. Plasmid visualisation in
agarose gels showed that the TEM-24 gene was
located on an 85-kb plasmid, the TEM-92 gene on
a 50-kb plasmid, and the TEM-52 gene on a 70-kb
plasmid. Isolate no. 12 contained both the 50-kb
and the 70-kb plasmids.
PFGE analysis and epidemiology of
ESBL-producing P. mirabilis isolates
The 45 SﬁI PFGE proﬁles grouped [24] into eight
pulsotypes (I–VIII; Table 2). The predominant
types were pulsotypes VI (12 isolates; 26.6%)
and IV (ten isolates; 22.3%). The 12 isolates
belonging to pulsotype VI were obtained between
1997 and 2001 from patients in different care
units. Similarly, the ten isolates belonging to
pulsotype IV were collected between 2001 and
2002 from patients hospitalised in various wards:
three in urology, two in geriatrics, and the
remaining ﬁve in different care units. Seven
isolates belonged to pulsotype I, of which three
were collected from patients hospitalised in the
same care unit (functional rehabilitation), two
from patients in the urology ward, and two others
from patients in different care units. All of these
isolates were recovered between 1977 and 2000.
Five isolates were collected in 2000 and belonged
to pulsotype II; these were obtained from patients
hospitalised in different wards, with the excep-
tion of two patients who were in the same
geriatric ward. Three isolates (two from urology
and one from a geriatric ward) belonging to
pulsotype III were isolated in 2000, and one
additional isolate was obtained in 1999 from the
urology ward. The two isolates of pulsotype V
and the four isolates of pulsotype VII were
collected between 1997 and 2001. The single
isolate of pulsotype VIII was obtained in 2002.
These results are shown in more detail in Tables 1
and 2.
The ﬁrst isolate of ESBL-producing P. mirabilis
was obtained in this hospital in February 1997
from a patient admitted to the urology ward
(patient 1). During the following months (March
to December 1997), multiresistant isolates of
P. mirabilis were obtained from another patient
hospitalised in the urology ward (patient 3) and
from patients in maxillofacial surgery (patient 2),
neurosurgery (patient 4), functional rehabilitation
(patient 5), vascular surgery (patient 7), and a
long-stay ward (patients 6 and 8) (Tables 1 and 2).
DISCUSSION
The overall prevalence rate (1.3%) of ESBL-pro-
ducing P. mirabilis observed in this study was
lower than rates reported elsewhere, and the
present study did not conﬁrm the suggestion that
ICUs play a major role in the intra-hospital
dissemination of epidemic multiresistant bacteria
[25]. In the present study, the urology, long-stay
and rehabilitation wards, which together accoun-
ted for 35.5% of all patients colonised ⁄ infected
with ESBL-producing P. mirabilis, played a pre-
dominant role in intra- and inter-ward dissemin-
ation. Many of these isolates were obtained from
elderly patients (mean age 63 years) hospitalised
in the urology (20%) or long-stay and rehabilit-
ation wards (15.5%), and most (53.3%) were
collected from urine, with a higher rate for men
(62.5%) than for women (37.5%). This higher rate
could be explained by the frequency of UTIs
observed in these units and by the presence of
P. mirabilis infections in elderly patients with
severe underlying disease or chronic illness. These
ﬁndings conﬁrm those reported previously [13].
In the present study, the high percentage of
community-acquired cases (37.7% of ESBL colo-
nised ⁄ infected patients) differed from previously
published ﬁgures of 8.7% [26], 1.5% [27] and
0.3% [28]. These variations might be explained by
the recruitment of different patient types and
variable epidemiological situations in different
hospitals or regions. The proportion of commu-
nity-acquired infections observed in the present
study may be an overestimation, caused by
factors such as hospitalisation at home, in private
healthcare centres, clinics, nursing homes, a stay
in follow-up care wards, empirical antibiotic
therapy or ‘contact’ with another carrier (e.g., in
the same family). Colodner et al. [6] conducted a
study in Afula, Israel, and found that the inde-
pendent risk factors for ESBL production in
isolates from non-hospitalised patients were pre-
vious hospitalisation in the past 3 months, anti-
biotic treatment in the past 3 months, age
> 60 years, diabetes and male gender. Most
patients hospitalised in ICUs are transferred to a
general acute-care unit, followed by a rest, nur-
sing or retirement home. Some of these patients
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may carry ESBL-producing Enterobacteriaceae for
prolonged periods, and continued carriage of
such strains may contribute to their extra-hospital
spread [29]. In addition, community-acquired
strains producing ESBLs might be selected from
the existing gastrointestinal ﬂora when it is
exposed to broad-spectrum antimicrobial agents
[30].
The levels of resistance to cefotaxime, ceftazi-
dime, cefepime, cefpirome and aztreonam varied
according to the isolate and enzyme type
involved, but all ESBL-producing isolates were
detected by the double-disk synergy test. The
relative MICs of cefotaxime and ceftazidime were
in accord with either the presence of an ESBL
with high hydrolytic activity against cefotaxime
(TEM-92 or TEM-52) or an ESBL with high
hydrolytic activity against ceftazidime (TEM-24)
[10,14,23,31]. TEM-92 and TEM-52 were encoded
by large plasmids that differed in size, but which
were associated with similar b-lactam resistance
markers. In contrast, the TEM-24 plasmid was
associated with different b-lactam resistance
markers. The results agreed with those reported
previously concerning TEM-92, TEM-52 and
TEM-24, which are encoded by 50-, 70- and
85-kb plasmids, respectively [10,23], although
Pai et al. [31] observed a great variability in
plasmid size (between 71 and 100 kb) among
TEM-52-producing E. coli and K. pneumoniae
isolates from Korea.
TEM-24 is produced predominantly by strains
of Ent. aerogenes [32], and the ﬁrst Ent. aerogenes
strains producing TEM-24 were reported in our
hospital in 1996, where they were responsible for
an epidemic that occurred between 1998 and 1999
[33]. The ﬁrst isolates of P. mirabilis producing
TEM-24 were observed in our hospital in Febru-
ary and March 1997. A TEM-92-producing
P. mirabilis strain was ﬁrst isolated in a French
hospital in 1998 [14], and it was during the same
year that a P. mirabilis isolate producing TEM-92
was identiﬁed in our laboratory. TEM-52 has been
reported previously in K. pneumoniae [23,31], and
subsequently in P. mirabilis isolates from Italy
[14]. The ﬁrst P. mirabilis isolate producing TEM-
52 in our hospital was isolated in January 1999.
The presence of these plasmid-mediated
b-lactamases in a hospital is a cause for concern.
According to the literature, there is an increas-
ing incidence of this kind of resistance in
many French hospitals. Polyclonal spread of
P. mirabilis isolates was observed in most wards
of the hospital. The easy transfer of the genes
conferring resistance indicates a risk of trans-
mission to other enterobacteria that could lead
to treatment failure. The diversity of b-lacta-
mases, and their association with resistance to
aminoglycosides, quinolones and trimethoprim–
sulphamethoxazole, suggests that resistant
strains of P. mirabilis could become a problem
in the context of nosocomial infection. The
frequency of infection in the community means
that resistant strains can be constantly re-intro-
duced into a hospital. The present investigation
also demonstrated the existence of several clus-
ters of P. mirabilis isolates. Certain strains were
disseminated widely in the hospital, and were
maintained during the study period, while
others showed limited spread over time.
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